Gene therapy shows promise for arrhythmogenic cardiomyopathy

Researchers evaluated the effectiveness of adeno-associated virus (AAV)-mediated Plakophilin 2 (PKP2) delivery in treating arrhythmogenic cardiomyopathy (ACM).

Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023 | Psychedelic Invest

Mydecine Innovations Group (OTC: MYCOF / FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental

August 15, 2023

Rapt cuts immunology program following clinical holds

Rapt Therapeutics is officially shelving its mid-stage immunology candidate after a case of liver failure triggered clinical holds earlier this year. Back in February, the

November 12, 2024

Orthopedics leaders watch procedure backlog, new technologies in 2024

Orthopedics companies are preparing for a return to normal after a few tumultuous years influenced by the COVID-19 pandemic. Last year, the medtech industry benefited

January 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.